Indiana Attorney General Sues Eli Lilly Over Alleged Insulin Price Manipulation
核心洞察
Indiana Attorney General Todd Rokita filed a lawsuit against Eli Lilly, alleging the company conspired with other manufacturers to artificially inflate insulin prices by more than 1,000% over the past decade.
The lawsuit claims insulin list prices increased dramatically to $300-700 per vial while manufacturing costs remained low at $2-4 per vial, forcing some diabetics to skip doses due to cost.
Despite Lilly's 2023 announcement of a 70% price cut and $35 monthly out-of-pocket cap, Rokita seeks damages and injunctive relief to drive structural market changes.
Indiana Attorney General Todd Rokita has filed a lawsuit against Indianapolis-based pharmaceutical giant Eli Lilly and Company, alleging the company participated in a conspiracy to artificially inflate insulin prices by more than 1,000% over the past decade. The legal action marks a significant escalation in the state's efforts to address what it characterizes as predatory pricing practices affecting diabetic patients across Indiana.
Allegations of Price Manipulation
The lawsuit accuses Lilly of collaborating with other insulin manufacturers and pharmacy benefit managers (PBMs) to dramatically increase insulin prices despite low manufacturing costs. According to the complaint, insulin list prices have surged to $300-700 per vial while production costs remain between $2-4 per vial. This pricing structure has created substantial financial barriers for diabetic patients, with some forced to skip or reduce doses—behavior that can lead to serious health complications, costly hospitalizations, or death.
"Pharmaceutical companies should not take advantage of Hoosiers or any other American—this includes Lilly, regardless of its Indiana roots," Rokita stated. The lawsuit contends that Indiana diabetics paid these "false" prices without knowing they were artificially inflated, as Lilly allegedly concealed pricing structures through "opaque" contracts.
Failed Negotiations Lead to Legal Action
The current lawsuit follows a similar action Rokita filed in March 2024 against other insulin manufacturers and PBMs, from which he initially excluded Eli Lilly based on the company's promise to engage in direct discussions with the state. However, despite what Rokita described as "productive" conversations, the negotiations "ultimately failed to make progress," prompting the attorney general to pursue legal action against the Indiana-based company.
The state alleges that Lilly and its competitors raised prices in lockstep with one another to maximize profits, then paid portions of those list prices to pharmacy benefit managers to maintain favorable access to PBM formularies—the lists of drugs that insurers will cover.
Company Response and Recent Price Reductions
Eli Lilly has strongly contested the allegations, with a company spokesperson calling the lawsuit "wasteful" and highlighting the company's recent affordability initiatives. "It is unfortunate that the Indiana AG would decide to spend state resources on such a wasteful lawsuit and sue an Indiana company that has led the way in making insulin more affordable for Americans," the spokesperson said.
The company points to significant pricing reforms implemented in recent years. In 2023, Lilly announced a 70% price cut for its most popular insulin products and established a $35 monthly out-of-pocket cost cap. According to the company, patients paid an average of less than $15 out-of-pocket for Lilly insulin in 2024. The company also notes its collaboration with the federal government to reduce Medicare insulin prices, even before lawsuits were filed.
Legal Framework and Broader Impact
Rokita is pursuing the case under multiple Indiana statutes, including the Indiana Deceptive Consumer Sales Act, Indiana Medicaid False Claims Act, and the Indiana Antitrust Act. The lawsuit seeks both monetary damages and injunctive relief to drive structural market changes in insulin pricing.
The complaint alleges that "the State has unknowingly overpaid millions of dollars every year for Eli Lilly's diabetes medications" due to the alleged pricing manipulation. Beyond financial recovery, the legal action aims to establish lasting accountability and prevent future pricing abuses.
The case represents part of a broader national effort to address insulin pricing, with the 2024 lawsuit against other manufacturers moved to federal court and incorporated into multi-district litigation in New Jersey. According to Rokita's office, other similar lawsuits have already prompted manufacturers, including Eli Lilly, to "substantially reduce prices and introduce $35 monthly out-of-pocket caps for many patients."